'Decoy' of androgen-responsive element induces apoptosis in LNCaP cells

Prostate

Volumn 41, Issue 2, 1999, Pages 121-126

  Kuratsukuri, Katsuyuki ^a   Sugimura, Kazunobu ^a   Harimoto, Kouji ^a   Kawashima, Hidenori ^a   Kishimoto, Taketoshi ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Androgen receptor; Androgen responsive element; Apoptosis; Decoy double stranded oligonucleotide; LNCaP; Prostate cancer

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANTIANDROGEN; DNA FRAGMENT; LIPOFECTIN; OLIGONUCLEOTIDE; PROSTATE SPECIFIC ANTIGEN;

APOPTOSIS; ARTICLE; CANCER HORMONE THERAPY; CELL PROLIFERATION; CONTROLLED STUDY; DNA TRANSFECTION; HORMONE RESPONSIVE ELEMENT; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTEIN DNA INTERACTION;

AMINO ACID SEQUENCE; APOPTOSIS; BINDING, COMPETITIVE; CELL DIVISION; HUMANS; MALE; MOLECULAR SEQUENCE DATA; OLIGONUCLEOTIDE PROBES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TUMOR CELLS, CULTURED;

EID: 0032847991     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19991001)41:2<121::AID-PROS6>3.0.CO;2-Q     Document Type: Article

References (24)

1. Crawford ED. Challenges in the management of prostate cancer. Br J Urol 1992;70:33-38.
2. Gaddipati JP, McLeod DG, Heidenberg HB, Sesterhenn IA, Finger MJ, Moul JW, Srivastava S. Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res 1994;54:2861-2864.
3. Suzuki H, Akakura K, Komiya A, Aida S, Shimazaki J. Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome. Prostate 1996;29:153-158.
4. Schoenberg MP, Hakimi JM, Wang S, Bova GS, Epstein JI, Fischbeck KH, Isaacs WB, Walsh PC, Barrack ER. Microsatellite mutation (CAG 24-18) in the androgen receptor gene in human prostate cancer. Biochem Biophys Res Commun 1994;198:74-80.
5. Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP. Mutation of the androgen receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995;332:1393-1398.
6. Trapman J, Brinkmann AO. The androgen receptor in prostate cancer. Pathol Res Pract 1996;192:752-760.
7. Kyprianou N, Isaacs JT. Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 1988;122: 552-562.
8. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP. LNCaP model of human prostatic carcinoma. Cancer Res 1983;43:1809-1818.
9. Schuurmans ALG, Bolt J, Veldscholte J, Mulder E. Stimulatory effects of antiandrogens on LNCaP human prostate tumor cell growth, EGF-receptor level and acid phosphatase secretion. J Steroid Biochem Mol Biol 1990;37:849-853.
10. Lee C, Sutkowski DM, Sensibar JA, Zelner D, Kim I, Amsel I, Shaw N, Prins GS, Kozlowski JM. Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone. Endocrinology 1995;136:796-803.
11. Riegman PHJ, Vlietstra RJ, van der Korput JAGM, Brinkmann AO, Trapman J. The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. Mol Endocrinol 1991;5:1921-1930.
12. Cleutjens KBJM, van Eekelen CCEM, van der Korput HAGM, Brinkmann AO, Trapman J. Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter. J Biol Chem 1996;271:6379-6388.
13. Kumar V, Chambon P. The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer. Cell 1988; 55:145-156.
14. Roche PJ, Hoare SA, Parker MG. A consensus DNA-binding site for the androgen receptor. Mol Endocrinol 1992;6:2229-2235.
15. Schuurmans ALG, Bolt J, Mulder E. Androgen stimulates both growth rate and epidermal growth factor receptor activity of the human prostate tumor cell LNCaP. Prostate 1988;12:55-63.
16. Schreiber E, Matthias P, Muler MM, Schaffner W. Rapid detection of octamer binding proteins with "mini-extracts," prepared from a small number of cells. Nucleic Acids Res 1989;17:6919.
17. Tilley WD, Wilson CM, Marcelli M, McPhaul MJ. Androgen receptor gene expression in human prostate carcinoma cell lines. Cancer Res 1990;50:5382-5386.
18. Dupont A, Gomez J, Cusan L, Koutsilieris M, Labrie F. Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J Urol 1993;150:908-913.
19. Scher HI, Kelly WK. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 1993;11:1566-1572.
20. Akakura K, Akimoto S, Ohki T, Shimazaki J. Antiandrogen withdrawal syndrome in prostate cancer after treatment with steroidal antiandrogen chlormadinone acetate. Urology 1995;45: 700-705.
21. Veldscholte J, Ris-Stalpers C, Kuiper GGMK, Berrevoets C, Claassen E, van Rooij HCJ, Trapman J, Brinkmann AO, Mulder E. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 1990;173:534-540.
22. Sullenger BA, Gallardo HF, Ungers GE, Gilboa E. Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication. Cell 1990;63:601-608.
23. Morishita R, Gibbons GH, Horiuchi M, Ellison KE, Nakajima M, Zhang L, Kaneda Y, Ogihara T, Dzau VJ. A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo. Proc Natl Acad Sci USA 1995;92:5855-5859.
24. Morishita R, Higaki J, Ogihara T. Application of transcription factor "decoy" strategy as means of gene therapy and study of gene expression in cardiovascular disease. Circ Res 1998;82: 1023-1028.